BioCurate, an independently operated joint venture between The University of Melbourne and Monash University, and NLC, the European Healthtech Venture Builder based in the Netherlands, announced today they have signed a Memorandum of Understanding (MoU), which paves the way for sharing of scientific and commercial expertise and collaboration on projects to bring new therapies to market.
BioCurate and NLC share complementary strengths which, when combined, could unlock vast potential for healthcare innovation. The partnership offers significant strategic value, as both share a similar mission; to transform top-tier innovations and ideas into life-changing products or services that advance health-related science.
Both companies target early-stage projects, and the partnership seeks to improve the chances of success of current and future projects in each organisation’s portfolio by improving their access to the scarce skills and resources required for the translation of scientific discoveries into commercially viable therapies.
The Hon. John Brumby AO, Chair of the BioCurate Board, said:
“We’re thrilled to expand BioCurate’s network of international strategic partners through this new agreement with NLC.
It takes a village to produce new, commercially viable therapies. This partnership helps to ensure the fantastic research taking place in Victoria’s leading academic laboratories has a better chance of becoming medicines that improve people’s lives. It also means NLC has access to the incredible talent we have in Victoria to support the success of the projects in their portfolio.”
Dr. Eric Hayes, Director of Partnerships at BioCurate, said:
“NLC was an obvious choice of partner for BioCurate because of the quality and breadth of its complementary expertise, as well as its presence in, and access to the European pharmaceutical market.
“We look forward to evaluating our combined project portfolio’s to identify specific opportunities for collaboration.”
Bert-Arjan Millenaar, CEO of NLC, commented:
“By collaborating with BioCurate, a leader in translating novel technologies to therapeutics, NLC is taking an exciting step forward in the biotech space and expands its expert network and reach to the southern hemisphere. We consider BioCurate a strategic partner for our joint mission to create novel therapies for unmet needs and we look forward to bringing science to life together.”
